These compelling results show for the first time that CCR3 is expressed in prostate cancer and that its expression, amplified in obesity, is correlated both with the occurrence of aggressive prostate cancer, BCR and surgical treatment failure. Here, CCR3 is linked to obesity due to melanocortin 4 receptor deficiency.